Key insights
- Exact Sciences shareholders approved the merger with Abbott Laboratories. While the merger itself is a significant event for the companies involved, it does not present a clear leading indicator for broader US equity market movements. The approval is subject to regulatory conditions, and the compensation vote's failure is an internal matter. The article focuses on corporate actions rather than macroeconomic trends or sector-wide shifts that would typically influence the overall market.
Exact Sciences Corp. (NASDAQ:EXAS) announced Friday that its shareholders have approved the company’s proposed merger with Abbott Laboratories (NYSE:ABT). The decision was made at a special meeting held the same day, according to a statement based on a Securities and Exchange Commission filing.
At the meeting, shareholders voted on three proposals. The primary item was the adoption of the merger agreement, under which Exact Sciences will merge with a subsidiary of Abbott Laboratories and become a wholly owned subsidiary of Abbott. Of the 190,810,202 shares eligible to vote, 128,906,310 shares, or 67.56%, were represented in person or by proxy, constituting a quorum.
The merger agreement proposal received 128,431,562 votes in favor, 386,941 votes against, and 87,807 abstentions. There were no broker non-votes. The proposal to approve, on a nonbinding advisory basis, the compensation that may be paid to Exact Sciences’ named executive officers in connection with the merger was not approved, receiving 42,290,727 votes in favor, 85,655,344 votes against, and 960,239 abstentions. The third proposal, which authorized the adjournment of the meeting if necessary to solicit additional proxies, was approved with 123,806,529 votes in favor, 4,845,599 against, and 254,182 abstentions.
Completion of the merger remains subject to customary closing conditions, including regulatory approvals.
The information in this article is based on a press release statement and the company’s SEC filing.
In other recent news, Exact Sciences Corp. has been in the spotlight due to a series of significant developments. The company announced the passing of federal legislation that establishes a pathway for Medicare coverage of multi-cancer early detection tests, aimed at addressing a major gap in cancer detection. Meanwhile, Exact Sciences is set to be acquired by Abbott Laboratories for $105 per share in cash, a transaction valued at approximately $21 billion in equity. This acquisition has led several analyst firms, including Mizuho, Stifel, and TD Cowen, to downgrade their ratings on Exact Sciences, although all raised their price targets to align with the acquisition price.
Additionally, Exact Sciences has accelerated the vesting and payment of annual bonuses and equity awards for its executive officers in light of the merger with Abbott. This decision was made to address potential tax implications under specific sections of the Internal Revenue Code. The acquisition deal values Exact Sciences at about 6.2 times Stifel’s 2026 revenue estimate of $3,643 million. These developments mark a pivotal moment for Exact Sciences as it transitions under the umbrella of Abbott Laboratories.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ABT plus thousands of other stocks and find your next hidden gem with massive upside.